Zhuang Wan-Chuan, Wu Qing-Yun, Meng Fan-Jing, Xu Kai-Lin
Department of Hematology, The Second People's Hospital of Lianyungang, Lianyungang 222023, Jiangsu Province, China.
Blood Diseases Institute, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Oct;28(5):1464-1467. doi: 10.19746/j.cnki.issn.1009-2137.2020.05.006.
To investigate the prognostic significance of CUEDC1 in patients with acute myeloid leukemia (non-M).
52 cases newly diagnosed AML (non-M) were selected and enrolled in AML non-M group, at the same time, 10 cases of iron doficiency anemia were selected and enrolled in control group. The bone marrow mononuclear cells(BMMC) were isolated from bone marrow of patients, the expression level of CUEDC1 in BMMC was detected by RT-PCR, the expression level of CUEDC1 mRNA in BMMC of AML-subtype patients was compared. The AML patients were divided into low and high expression groups according to the expression level of CUEDC1 mRNA, and the complete remission rate after the first chemothrapy course was compared, and the relative expression level of CUEDC1 mRNA between the remission and the non-remission group were compared.
CUEDC1 was expressed in BMMC of 52 newly diagnosed patients with AML (non-M) of all subtypes, which was higher than that in control group (P<0.05), and the expression level of CUEDC1 mRNA in M patients was the highest (P<0.05). In CUEDC1 low expression group, induced complete remisson rate （76.2%,16/21） after the first course of treatment seemed higher than that of the high expression group（67.7%,21/31）, but the difference was not statistically significant; the expression level of CUEDC1 mRNA in the remission group of patients with newly diagnosed AML(non-M) was lower than that in the non-remission group(P<0.05).
CUEDC1 is highly expressed in newly diagnosed patients with AML, among which the CUEDC1 mRNA expression level in M patients is the highest, the expression of CUEDC1 mRNA possibly relates to the prognosis of patients with AML.
